vs
Side-by-side financial comparison of JFrog Ltd (FROG) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
JFrog Ltd is the larger business by last-quarter revenue ($145.3M vs $123.8M, roughly 1.2× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -10.5%, a 13.8% gap on every dollar of revenue. On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs 4.7%). JFrog Ltd produced more free cash flow last quarter ($49.9M vs $7.6M). Over the past eight quarters, JFrog Ltd's revenue compounded faster (20.4% CAGR vs 5.6%).
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
FROG vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $145.3M | $123.8M |
| Net Profit | $-15.2M | $4.1M |
| Gross Margin | 77.9% | 72.5% |
| Operating Margin | -14.7% | 4.3% |
| Net Margin | -10.5% | 3.3% |
| Revenue YoY | 25.2% | 4.7% |
| Net Profit YoY | 34.4% | 1379.4% |
| EPS (diluted) | $-0.13 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $145.3M | $123.8M | ||
| Q3 25 | $136.9M | $128.3M | ||
| Q2 25 | $127.2M | $114.8M | ||
| Q1 25 | $122.4M | $113.2M | ||
| Q4 24 | $116.1M | $118.2M | ||
| Q3 24 | $109.1M | $114.6M | ||
| Q2 24 | $103.0M | $110.6M | ||
| Q1 24 | $100.3M | $111.0M |
| Q4 25 | $-15.2M | $4.1M | ||
| Q3 25 | $-16.4M | $5.3M | ||
| Q2 25 | $-21.7M | $5.3M | ||
| Q1 25 | $-18.5M | $4.7M | ||
| Q4 24 | $-23.2M | $-321.0K | ||
| Q3 24 | $-22.9M | $4.3M | ||
| Q2 24 | $-14.3M | $1.3M | ||
| Q1 24 | $-8.8M | $2.3M |
| Q4 25 | 77.9% | 72.5% | ||
| Q3 25 | 77.4% | 73.3% | ||
| Q2 25 | 76.3% | 71.7% | ||
| Q1 25 | 75.3% | 72.1% | ||
| Q4 24 | 75.4% | 72.0% | ||
| Q3 24 | 75.0% | 71.3% | ||
| Q2 24 | 78.8% | 71.4% | ||
| Q1 24 | 79.5% | 71.2% |
| Q4 25 | -14.7% | 4.3% | ||
| Q3 25 | -15.8% | 7.0% | ||
| Q2 25 | -20.4% | 3.7% | ||
| Q1 25 | -18.8% | 5.4% | ||
| Q4 24 | -21.9% | 3.8% | ||
| Q3 24 | -27.4% | 4.6% | ||
| Q2 24 | -18.6% | 5.1% | ||
| Q1 24 | -16.6% | 4.2% |
| Q4 25 | -10.5% | 3.3% | ||
| Q3 25 | -12.0% | 4.2% | ||
| Q2 25 | -17.0% | 4.6% | ||
| Q1 25 | -15.1% | 4.2% | ||
| Q4 24 | -20.0% | -0.3% | ||
| Q3 24 | -21.0% | 3.8% | ||
| Q2 24 | -13.9% | 1.2% | ||
| Q1 24 | -8.8% | 2.1% |
| Q4 25 | $-0.13 | $0.23 | ||
| Q3 25 | $-0.14 | $0.30 | ||
| Q2 25 | $-0.19 | $0.28 | ||
| Q1 25 | $-0.16 | $0.25 | ||
| Q4 24 | $-0.21 | $-0.02 | ||
| Q3 24 | $-0.21 | $0.23 | ||
| Q2 24 | $-0.13 | $0.07 | ||
| Q1 24 | $-0.08 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $704.4M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $887.4M | $161.6M |
| Total Assets | $1.3B | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $704.4M | $93.9M | ||
| Q3 25 | $651.1M | $95.6M | ||
| Q2 25 | $611.7M | $81.3M | ||
| Q1 25 | $563.5M | $86.5M | ||
| Q4 24 | $522.0M | $84.7M | ||
| Q3 24 | $467.8M | $78.7M | ||
| Q2 24 | $591.3M | $68.7M | ||
| Q1 24 | $579.6M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $887.4M | $161.6M | ||
| Q3 25 | $859.4M | $166.7M | ||
| Q2 25 | $826.5M | $163.7M | ||
| Q1 25 | $800.0M | $167.1M | ||
| Q4 24 | $773.5M | $161.0M | ||
| Q3 24 | $756.2M | $162.6M | ||
| Q2 24 | $721.4M | $156.4M | ||
| Q1 24 | $707.8M | $159.7M |
| Q4 25 | $1.3B | $261.1M | ||
| Q3 25 | $1.3B | $264.8M | ||
| Q2 25 | $1.2B | $254.9M | ||
| Q1 25 | $1.2B | $252.7M | ||
| Q4 24 | $1.1B | $240.9M | ||
| Q3 24 | $1.1B | $245.3M | ||
| Q2 24 | $1.0B | $235.8M | ||
| Q1 24 | $997.1M | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.7M | $9.9M |
| Free Cash FlowOCF − Capex | $49.9M | $7.6M |
| FCF MarginFCF / Revenue | 34.3% | 6.1% |
| Capex IntensityCapex / Revenue | 0.6% | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $142.3M | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.7M | $9.9M | ||
| Q3 25 | $30.2M | $18.5M | ||
| Q2 25 | $36.1M | $4.3M | ||
| Q1 25 | $28.8M | $2.6M | ||
| Q4 24 | $49.1M | $12.2M | ||
| Q3 24 | $27.6M | $9.6M | ||
| Q2 24 | $16.7M | $1.3M | ||
| Q1 24 | $17.5M | $2.2M |
| Q4 25 | $49.9M | $7.6M | ||
| Q3 25 | $28.8M | $16.8M | ||
| Q2 25 | $35.5M | $3.0M | ||
| Q1 25 | $28.1M | $1.5M | ||
| Q4 24 | $48.5M | $10.0M | ||
| Q3 24 | $26.7M | $7.9M | ||
| Q2 24 | $16.0M | $-2.0M | ||
| Q1 24 | $16.6M | $-1.5M |
| Q4 25 | 34.3% | 6.1% | ||
| Q3 25 | 21.0% | 13.1% | ||
| Q2 25 | 27.9% | 2.6% | ||
| Q1 25 | 23.0% | 1.3% | ||
| Q4 24 | 41.8% | 8.5% | ||
| Q3 24 | 24.5% | 6.9% | ||
| Q2 24 | 15.5% | -1.9% | ||
| Q1 24 | 16.6% | -1.4% |
| Q4 25 | 0.6% | 1.9% | ||
| Q3 25 | 1.0% | 1.3% | ||
| Q2 25 | 0.5% | 1.2% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 0.5% | 1.9% | ||
| Q3 24 | 0.9% | 1.5% | ||
| Q2 24 | 0.7% | 3.0% | ||
| Q1 24 | 0.8% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | — | 0.97× | ||
| Q1 24 | — | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FROG
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
